Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. (2016)

First Author: Lochhead PA
Attributed to:  Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1080/15384101.2015.1120915

PubMed Identifier: 26959608

Publication URI: http://europepmc.org/abstract/MED/26959608

Type: Journal Article/Review

Volume: 15

Parent Publication: Cell cycle (Georgetown, Tex.)

Issue: 4

ISSN: 1551-4005